基于微RNA的治疗GATA2缺陷血管疾病

Dorothee Hartmann¹, Jan Fiedler¹, Kristina Sonnenschein¹+16

• ¹From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.).+1